Idneo has successfully completed the development and validation of Innitius’s CerviSense probe. This joint project, which began in 2022, marks a paradigm shift in gynecology by introducing the first device designed specifically to aid medical decision-making in the face of the threat of preterm birth (PTL).
CerviSense can determine whether labor will occur within the next seven days, using torsional waves that propagate through the cervical tissue. The device captures measurements of cervical tissue stiffness and sends them to an artificial intelligence algorithm that combines them with the patient’s medical history to estimate a percentage risk of preterm birth. This innovation enables healthcare professionals to rely on real-world evidence to avoid transfers, hospitalizations, and unnecessary pharmacological treatments, thereby improving care and patient wellbeing.
The close of this phase coincides with Innitius obtaining the CE certification, a milestone that marks the beginning of the device’s commercialization.
Daniel Fernández-Capo, Idneo’s CEO, stated: “The success of CerviSense after years of joint effort with Innitius reflects our true purpose in the MedTech sector. Beyond solving a highly complex engineering challenge, our goal is to put technology at the service of health to transform clinical practice. This device provides a real answer to a global gynecology problem, directly enhancing people’s well-being.”
With the completion of this project, Idneo reaffirms its status as a global technology partner capable of delivering value in high-complexity medical devices, from conceptual design through regulatory compliance and industrialization toward the market. The company brings its industrial strength to ensure that innovation translates into diagnostic solutions that optimize health system management and guarantee patient safety.
